TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29231584
Drug: Granisetron hydrochloride
Normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron hydrochloride injection, 3 mg before and after cisplatin chemotherapy, for 3 days
Study: 29231584
Drug: Granisetron hydrochloride
Normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron hydrochloride injection
Study: 26186566
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of cholecalciferol
Study: 21903745
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy with cisplatin (100 mg/m2 on days 1 and 29, vinblastine at 5 mg/m2 per week for 5 weeks) and TRT (63 Gy delivered as once-daily fractions beginning on day 50)
Study: 21903745
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with cisplatin (100 mg/m2) and TRT (63 Gy delivered as once-daily fractions beginning on day 1)
Study: 21903745
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with cisplatin (50 mg/m2 on days 1, 8, 29, and 36) and oral etoposide (50 mg twice daily for 10 weeks on days 1, 2, 5, and 6) with TRT (69.6 Gy delivered as 1.2 Gy twice-daily fractions beginning on day 1)
Study: 8901660
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d aspirin
Study: 16676655
Drug: Midodrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (10 mg, orally) administered after landing approximately 1 h before testing
Study: 15316165
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day oral finasteride for 12 months
Study: 15316165
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical minoxidil solution applied twice daily for 12 months
Study: 3838401
Drug: molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: molsidomine (2 mg intravenously)
Study: 3838401
Drug: isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isosorbide dinitrate (ISDN) (5 mg sublingually)
Study: 2906956
Drug: nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (20 mg sublingually)
Study: 27287235
Drug: Dolutegravir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir monotherapy (50 mg/day)
Study: 24933430
Drug: 6% CHO‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% CHO‐electrolyte solution
Study: 24933430
Drug: Electrolyte (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte (placebo) solution
Study: 26051481
Drug: Enzyme Replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme Replacement Therapy (ERT)
Study: 18157595
Drug: Symphytum herb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symphytum herb extract cream (10% active ingredient)
Study: 16185409
Drug: Negative charge
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative charge aerosol (NCA) treatment for 1.5 hours, 1-2 times a day, from 6 postburn hours to 2 postburn days.
Study: 16185409
Drug: Negative charge
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative charge aerosol (NCA) treatment in self control group with sterile schissel coverage.
Study: 16185409
Drug: Negative charge
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative charge aerosol (NCA) treatment in trial group.
Study: 16185409
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in control group.
Study: 16185409
Drug: Pathological examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pathological examination in rats treated with conventional treatment.
Study: 14640055
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors
Study: 320995
Drug: Clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clobetasone butyrate ointment
Study: 320995
Drug: Flurandrenolone ointment
Normalized name: Flurandrenolone
DrugBank: Flurandrenolide acetate (DB14673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurandrenolone ointment
Study: 30205315
Drug: Chlorella supplementation
Normalized name: Chlorella emersonii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella supplementation (1500 mg/day for 8 weeks)
Study: 30407136
Drug: Hydrocortisone and
Normalized name: hydrocortisone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone and Yohimbine (both drugs)
Study: 29056008
Drug: Peg‐IFN‐α‐2b (Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN‐α‐2b (Y shape, 40 kD) injection (180 μg/week)
Study: 18042501
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI)
Study: 23809140
Drug: Non-nucleosidic reverse
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleosidic reverse transcriptase inhibitor (NNRTI)
Study: 17014541
Drug: Xeno III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xeno III (self-etching priming agent)
Study: 17165277
Drug: Montelukast, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 10 mg/d
Study: 17336941
Drug: Naltrexone 0
Normalized name: MORPHINE 20MG/NALTREXONE 0.8MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 0 mg/day (placebo)
Study: 9306297
Drug: Progressive relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive relaxation and visualization treatment (6 hour-long sessions over 3 weeks)
Study: 9306297
Drug: Psychoeducational addiction
Normalized name: DRUGS USED IN ADDICTIVE DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational addiction treatment group
Study: 8320604
Drug: Synthetic surfactant
Normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic surfactant administration
Study: 3578725
Drug: Droperidol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.1 mg/kg with fentanyl 3.0 micrograms/kg (group 2)
Study: 30730774
Drug: Collaborative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative and Proactive Solutions (CPS)
Study: 25149412
Drug: Oxytocin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (24 IU intranasal single dose)
Study: 22234020
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 mcg/kg)
Study: 9024174
Drug: DuP 532
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP 532 (200 mg)
Study: 9024174
Drug: DuP 532
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuP 532 and Losartan (24 hours after dosing)
Study: 3477986
Drug: Local oestriol
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local oestriol treatment for 3 weeks
Study: 3477986
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar ointment without oestriol) for 3 weeks
Study: 30631386
Drug: FNB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of MgS 15% (450 mg)
Study: 30631386
Drug: FNB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of normal saline solution
Study: 17917738
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg/0.05 ml, three injections at 6-week intervals
Study: 17917738
Drug: Combined intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravitreal bevacizumab (IVB) and triamcinolone (IVT) 1.25 mg/0.05 ml and 2 mg/0.05 ml respectively, followed by two injections of IVB at 6-week intervals
Study: 23924918
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (control group)
Study: 29873004
Drug: Higher starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Higher starting dose of basal insulin glargine (0.3 U/kg)
Study: 29873004
Drug: Standard starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard starting dose of basal insulin glargine (0.2 U/kg)
Study: 27346552
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral vitamin K (LDVK) 150 mcg daily for six months
Study: 27346552
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral vitamin K (LDVK)
Study: 22167126
Drug: Overnight modest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight modest hyperinsulinaemia (average ≈ 286 pmol/l)
Study: 22167126
Drug: Marked hyperinsulinaemia
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marked hyperinsulinaemia during the clamp (average steady-state insulin ≈ 900 pmol/l)
Study: 17484484
Drug: 80 watt
Normalized name: Silver wattle pollen
DrugBank: Acacia dealbata pollen (DB15504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 watt KTP-laser treatment for small adenomas
Study: 17484484
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of KTP-laser and TUR-P for great adenomas
Study: 31111235
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment for primary prevention of ASCVD in patients older than 75 years
Study: 31111235
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment for secondary prevention of ASCVD in patients older than 75 years
Study: 31111235
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment initiation before 75-80 years
Study: 31111235
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of statin treatment when palliative treatment starts
Study: 23578453
Drug: Multimodal-antiemetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal-antiemetic therapy (group M) including target-controlled infusion of propofol and remifentanil, prophylactic dexamethasone 10 mg, tropisetron 4 mg, and parecoxib sodium 40 mg 30 minutes before the end of surgery
Study: 23578453
Drug: Ondansetron control
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron control (group C) including sevoflurane and 50% nitrous oxide, prophylactic ondansetron 4 mg 30 minutes before the end of surgery
Study: 19799471
Drug: Duodenal levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Duodenal levodopa infusion (DLI)
Study: 7104182
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral therapy
Study: 16945766
Drug: Adjuvant vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant vinorelbine plus cisplatin (30 mg/m² vinorelbine plus 100 mg/m² cisplatin)
Study: 10394407
Drug: 3-D conformal
Normalized name: trans-resveratrol 3-β-D-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-D conformal photon radiotherapy at a dose of 66 Gy
Study: 8871870
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 or 24 months)
Study: 1996795
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g milk chocolate‐charcoal mixture
Study: 1996795
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g SuperChar Liquid
Study: 1996795
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g Actidose Aqua activated charcoal
Study: 6350078
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus insulin
Study: 6350078
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and sulphonylurea therapy
Study: 22081522
Drug: Asacol 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol 2.4 g once daily (OD)
Study: 22081522
Drug: Asacol 800
Normalized name: mesalamine 800 MG [Asacol]
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asacol 800 mg three times daily (TDS)
Study: 20206793
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of oral piroxicam 20 mg
Study: 15924753
Drug: Surfactant (Curosurf)
Normalized name: Curosurf
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surfactant (Curosurf) 200 mg/kg initial dose, repeated doses of 200, 100, and 100 mg/kg at 6-12 hour intervals, maximum of four doses if OI deteriorated by > 2 from baseline
Study: 12813474
Drug: Oral hydrocortisone
Normalized name: hydrocortisone Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrocortisone 50 mg
Study: 12813474
Drug: Corticosteroid synthesis
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid synthesis inhibitor metyrapone 1500 mg orally
Study: 12813474
Drug: Methamphetamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine 0.5 mg/kg
Study: 10585796
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of co-trimoxazole
Study: 10585796
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of co-trimoxazole
Study: 1654967
Drug: Pipecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium 0.1 mg kg‐1
Study: 2877682
Drug: Tubocurarine 0.5
Normalized name: tubocurarine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine 0.5 mg kg‐1
Study: 31037449
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose rabeprazole (10 mg/day) + HST (7.5 g/day)
Study: 31037449
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose rabeprazole (20 mg/day)
Study: 21993580
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (estradiol associated with trimegestone)
Study: 19447518
Drug: Sequential prediction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential prediction algorithm based on viral kinetics at weeks 2 and 4
Study: 17901791
Drug: Comparator (amoxicillin/clavulanate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (amoxicillin/clavulanate, ceftriaxone, clarithromycin, or erythromycin lactobinate)
Study: 8078953
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg paroxetine per day
Study: 2688529
Drug: Iopromide 370
Normalized name: IOPROMIDE 370mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide 370 mgI/ml
Study: 29959901
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives 1 (20μg EE/150μg desogestrel)
Study: 29959901
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives 2 (30μg EE/3mg drospirenone)
Study: 29959901
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives 1 and 2
Study: 26628523
Drug: Pain exposure
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain exposure physical therapy (PEPT)
Study: 23789215
Drug: Acupoint-combination stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint-combination stimulation group
Study: 21671752
Drug: DPI-C (dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI-C (dry powder inhaler with ∼10% less of each drug per metered dose)
Study: 21671752
Drug: DPI-A (Advair
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI-A (Advair Diskus®, GlaxoSmithKline, delivering 100 μg fluticasone propionate and 50 μg salmeterol)
Study: 11015169
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors)
Study: 8730243
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg b.d.
Study: 6231893
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg b.d.
Study: 1382255
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy and radiotherapy (3 courses of chemotherapy with cisplatin 100 mg/m2, day 1 and etoposide 125 mg/m2 i.v., day 1; 250 mg/m2 p.o., day 2-3, followed by radiotherapy 4,000 cGy/20 fractions/4 weeks)
Study: 2580182
Drug: Captopril +
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril + Propranolol + Diuretic
Study: 30046837
Drug: MDCO-216 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO-216 (20 mg/kg weekly for 5 weeks)
Study: 22123525
Drug: Dexpanthenol cream
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexpanthenol cream once daily (B)
Study: 22123525
Drug: wIRA irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: wIRA irradiation for 30 min once daily together with dexpanthenol cream once daily (D)
Study: 22123525
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (A)
Study: 22123525
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (B-D)
Study: 15855263
Drug: L-T(4) replacement
Normalized name: L-3972-T
DrugBank: L-3972-T (DB17441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T(4) replacement
Study: 12421103
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 to 600mg followed by oral misoprostol 0.4 to 0.6mg or vaginal gemeprost 1.0mg/misoprostol 0.8mg
Study: 2122251
Drug: Heparin (5000-unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000-unit bolus followed by continuous intravenous heparin)
Study: 2122251
Drug: Aspirin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (80 mg daily oral)
Study: 22157279
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg BID
Study: 22157279
Drug: Naproxen 300
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 300 mg BID
Study: 22157279
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride 750 mg BID
Study: 17569792
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eccentric training and AirHeel brace
Study: 15788347
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy aimed at restoring dynamic stabilizing mechanisms and muscle co‐ordination at the shoulder
Study: 15788347
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physical modalities and range of motion exercises
Study: 1790251
Drug: Prophylactic indomethacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic indomethacin, 0.2 mg/kg, i.v. 24 h after birth
Study: 6759136
Drug: Carprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (100 mg in the morning plus 200 mg in the evening)
Study: 6759136
Drug: Carprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (100 mg 3 times daily)
Study: 31284844
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual daily lifestyle)
Study: 22786569
Drug: Losartan/HCTZ (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/HCTZ (50 mg losartan + 12.5 mg hydrochlorothiazide per day)
Study: 22786569
Drug: Maximal-dose ARB
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal-dose ARB
Study: 12399289
Drug: Purified isoflavone
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified isoflavone preparation (formulation A) with a genistein dose of 2, 4, 8, or 16 mg/kg body wt
Study: 12399289
Drug: Purified isoflavone
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified isoflavone preparation (formulation A)
Study: 7477218
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of lamivudine every 12 hours
Study: 7477218
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of zidovudine every 8 hours
Study: 7477218
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of lamivudine every 12 hours plus zidovudine
Study: 7477218
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of lamivudine every 12 hours plus zidovudine
Study: 2155751
Drug: 400 units
Normalized name: alpha-D-galactosidase 400 units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 units of intranasal calcitonin